RxDoctor Payments Data

Mark Cagle, PA

Medical · Surprise, AZNPI 1255950127

Payments from drug & device makers

$3,400in general payments, 2019–2025

Across 176 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$424
  • Novo Nordisk$354
  • AbbVie$340
  • Boehringer Ingelheim$306
  • GSK$251
  • Pfizer$228
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,400 in reported general payments places this provider in the 75th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$28,797
Medicare patients
189
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$16,068
EliquisApixaban13$10,900
PaxlovidNirmatrelvir/Ritonavir34$1,352
Albuterol Sulfate HfaAlbuterol Sulfate45$1,106
Methylprednisolone169$1,091
Duloxetine Hcl22$957
Atorvastatin Calcium77$896
Levothyroxine Sodium68$823
Gabapentin48$765
Losartan Potassium55$665
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav79$546
Pantoprazole Sodium31$508
Rosuvastatin Calcium36$500
Simvastatin36$489
Ondansetron OdtOndansetron22$413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$354$16,06816 claims
PfizerEliquis, Paxlovid$228$12,25247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 748 medical providers in Arizona.

Other medical in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →